1,628 Shares in Intuitive Surgical, Inc. (NASDAQ:ISRG) Bought by Net Worth Advisory Group

Net Worth Advisory Group purchased a new stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 1,628 shares of the medical equipment provider’s stock, valued at approximately $800,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of ISRG. Mirador Capital Partners LP grew its holdings in Intuitive Surgical by 1.4% during the third quarter. Mirador Capital Partners LP now owns 3,526 shares of the medical equipment provider’s stock worth $1,732,000 after purchasing an additional 50 shares during the period. Advisors Asset Management Inc. boosted its stake in shares of Intuitive Surgical by 18.1% during the 1st quarter. Advisors Asset Management Inc. now owns 7,380 shares of the medical equipment provider’s stock worth $2,945,000 after acquiring an additional 1,129 shares during the period. Healthcare of Ontario Pension Plan Trust Fund increased its holdings in shares of Intuitive Surgical by 617.1% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 89,069 shares of the medical equipment provider’s stock worth $39,622,000 after acquiring an additional 76,649 shares during the last quarter. Brookstone Capital Management raised its stake in Intuitive Surgical by 22.4% in the 2nd quarter. Brookstone Capital Management now owns 12,530 shares of the medical equipment provider’s stock valued at $5,340,000 after acquiring an additional 2,289 shares during the period. Finally, M&G Plc lifted its holdings in Intuitive Surgical by 53.5% during the 2nd quarter. M&G Plc now owns 5,069 shares of the medical equipment provider’s stock valued at $2,256,000 after purchasing an additional 1,766 shares during the last quarter. Institutional investors own 83.64% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Mizuho upped their price objective on shares of Intuitive Surgical from $440.00 to $500.00 in a report on Thursday. Oppenheimer reiterated a “market perform” rating on shares of Intuitive Surgical in a research note on Friday. Redburn Atlantic upgraded shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $380.00 to $510.00 in a research report on Friday, August 2nd. Morgan Stanley upped their target price on Intuitive Surgical from $375.00 to $460.00 and gave the company an “equal weight” rating in a research report on Monday, July 15th. Finally, Barclays lifted their price target on Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a report on Thursday, July 18th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and a consensus target price of $503.75.

Intuitive Surgical Trading Up 10.0 %

Shares of Intuitive Surgical stock opened at $521.15 on Friday. The firm has a market capitalization of $184.85 billion, a PE ratio of 94.07, a price-to-earnings-growth ratio of 5.40 and a beta of 1.39. The firm’s 50 day moving average is $483.85 and its 200 day moving average is $437.79. Intuitive Surgical, Inc. has a 1 year low of $254.85 and a 1 year high of $523.34.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.24. The company had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The company’s revenue for the quarter was up 14.5% compared to the same quarter last year. During the same period in the prior year, the business earned $1.18 earnings per share. As a group, research analysts anticipate that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Robert Desantis sold 1,413 shares of Intuitive Surgical stock in a transaction on Friday, July 26th. The shares were sold at an average price of $438.60, for a total transaction of $619,741.80. Following the transaction, the executive vice president now owns 5,506 shares in the company, valued at approximately $2,414,931.60. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Amy L. Ladd sold 450 shares of the company’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $490.28, for a total transaction of $220,626.00. Following the sale, the director now owns 821 shares in the company, valued at $402,519.88. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Robert Desantis sold 1,413 shares of the firm’s stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $438.60, for a total value of $619,741.80. Following the sale, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at $2,414,931.60. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 53,120 shares of company stock valued at $25,528,753 in the last 90 days. Corporate insiders own 0.90% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.